Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approval of Intragastric Balloon System

Device assists adults with weight management

Indications: The ORBERA Intragastric Balloon System is indicated for adult obese patients who have a body mass index (BMI) of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise.

Mechanism of action: The temporary system is placed into the stomach through the mouth, helps patients lose weight and should be removed after 6 months.

Efficacy and safety: In a clinical trial, 255 patients who used the system lost an average of 22 pounds. The device should not be used in patients who already have an intragastric balloon, have had prior gastrointestinal or bariatric surgery, or have any inflammatory disease of the GI tract.

Citation: FDA website. ORBERA intragastric balloon system. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapp.... Updated August 6, 2015. Accessed August 11, 2015.

This Week's Must Reads

No Need to Alter TKI Treatment in These Patients, Am J Hematol; ePub 2017 Oct 13; Alhuraiji, et al

Insurance Subsidy Impact on New TKI Users Assessed, Cancer; ePub 2017 Oct 4; Shen, Zhao, Liu, et al

Ruxolitinib in Patients Who Can’t Take Hydroxyurea, Blood; 2017 Oct 12; Verstovsek, Passamonti, et al

Socioeconomic Status Impact on Chronic GVHD, Biol Blood Marrow Transplant; ePub 2017 Oct 12; Hamilton, et al

Impact of Precision-Dosing Strategy with IVIG, Pharmacotherapy; ePub 2017 Oct 13; Stump, et al

Must Reads in Obesity

Metabolic Outcomes After Gastric Bypass Surgery, N Engl J Med; 2017 Sep 21; Adams, et al

Weight Gain & Odds of Healthy Aging, JAMA; 2017 Jul 18; Zheng, Manson, et al

Improved Diet Quality & Mortality Risks, N Engl J Med; 2017 Jul 13; Sotos-Prieto, et al

New Dietary Guidelines for Americans, DHHS/USDA guidelines target chronic diseases

Excess Sodium Intake in the US, Study looks at prevalence and risks